STOCK TITAN

MacroGenics swings to $20.1M loss in Q3 2026

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

MacroGenics (MGNX) reported third-quarter 2026 revenue of $18.7 million, compared with $53.0 million a year earlier, and a net loss of $20.1 million versus net income of $16.8 million. Revenue included $10.0 million related to Gilead’s option exercise, compared with $50.0 million of milestone revenue recognized in 2025; a $5.3 million increase in ZYNYZ royalty revenue partly offset the decrease. Cash, cash equivalents and marketable securities were $287.7 million as of September 30, 2026, compared with $189.9 million as of December 31, 2025. Third-quarter receipts included $119.6 million from Bora related to the sale of GMP manufacturing operations and a $24.5 million Sanofi regulatory milestone. MacroGenics expects its cash and projected and anticipated future partner payments to support runway through 2028.

The company completed MGC028 Phase 1 dose escalation, selected a lead indication and plans to initiate a randomized evaluation of two dose levels in that indication by year end 2026; as of October 10, 2026, no dose-limiting toxicities, ILD or ocular toxicity were reported. MGC030’s first Phase 1 patient was dosed. MGC026 enrollment completion is expected by year end 2026, with updated data expected in mid-2027; updated lorigerlimab results are expected in the first half of 2027.

1 point · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Major pointBora sale generated $119.6 million in third-quarter cash consideration. 81% of market cap

Negative

  • Moderate pointThird-quarter revenue was $18.7 million, versus $53.0 million a year earlier.
  • Moderate pointThird-quarter net loss was $20.1 million, versus $16.8 million net income a year earlier.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash, cash equivalents and marketable securities $287.7 million As of September 30, 2026; $189.9 million as of December 31, 2025.
Total revenue $18.7 million Quarter ended September 30, 2026; $53.0 million in the prior-year quarter.
Net income (loss) $20.1 million net loss Quarter ended September 30, 2026; $16.8 million net income in the prior-year quarter.
Research and development expenses $30.6 million Quarter ended September 30, 2026; $32.7 million in the prior-year quarter.
General and administrative expenses $8.4 million Quarter ended September 30, 2026; $9.9 million in the prior-year quarter.
Bora cash consideration $119.6 million Received during the third quarter in connection with the sale of GMP manufacturing operations.
Sanofi regulatory milestone payment $24.5 million Received during the third quarter.
Gilead option license payment $10.0 million Triggered by Gilead’s option exercise under the collaboration agreement.
antibody-drug conjugate (ADC) technical
"novel topoisomerase I inhibitor-based antibody-drug conjugate (ADC)"
An antibody-drug conjugate (ADC) is a targeted medical treatment that combines an antibody, which acts like a guided missile seeking out specific cells, with a powerful drug to destroy those cells. It is designed to deliver medication directly to diseased cells, minimizing damage to healthy tissue. For investors, ADCs represent innovative therapies with potential for high growth, especially if they prove effective in treating difficult-to-cure conditions.
T-cell engager (TCE) technical
"T-cell engager (TCE) and dual checkpoint inhibitor molecules"
A T‑cell engager (TCE) is a type of drug that acts like a matchmaker between a patient’s immune T cells and disease cells (often cancer), physically bringing them together so the immune cell can kill the target. Investors care because TCEs can deliver highly targeted treatments with the potential for strong clinical benefit and large market value, but they also carry development, safety and regulatory risks that can sharply affect company prospects.
bispecific DART® molecule technical
"PD-1 × CTLA-4 bispecific DART® molecule"
Investigational New Drug (IND) application regulatory
"clearance of the Investigational New Drug (IND) application"
An investigational new drug (IND) application is a formal request submitted to a drug regulator asking permission to begin testing a new medicine in people. It compiles lab results, manufacturing details and proposed human trial plans so regulators can judge safety before human studies start; for investors, an accepted IND is a key milestone that opens the clinical development pathway and can materially change a company’s risk profile and potential value, like getting a license to road-test a prototype.
dose-limiting toxicities medical
"there were no dose-limiting toxicities"
Dose-limiting toxicities are the harmful side effects seen in early clinical trials that are severe enough to stop researchers from raising a drug’s dose. Like a car’s speed limiter marking the safe top speed, DLTs define the maximum tolerable dose, and they matter to investors because they determine whether a medicine can reach effective levels, influence development timelines, costs, and regulatory chances, and thus affect a drug’s commercial prospects.
Simon 2-stage monotherapy cohort medical
"ongoing 40-patient SCCHN Simon 2-stage monotherapy cohort"
Total revenue $18.7 million Compared with $53.0 million for the quarter ended September 30, 2025.
Net income (loss) $20.1 million net loss Compared with $16.8 million net income for the quarter ended September 30, 2025.
Research and development expenses $30.6 million Compared with $32.7 million for the quarter ended September 30, 2025.
General and administrative expenses $8.4 million Compared with $9.9 million for the quarter ended September 30, 2025.
Cash, cash equivalents and marketable securities $287.7 million Compared with $189.9 million as of December 31, 2025.
Guidance

Cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026, together with projected and anticipated future payments from partners, are expected to support cash runway through 2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue and net income did MacroGenics (MGNX) report for Q3 2026?

MacroGenics reported $18.7 million in revenue and a $20.1 million net loss for the quarter ended September 30, 2026. Revenue was $53.0 million and net income was $16.8 million in the prior-year quarter.

How long does MacroGenics (MGNX) expect its cash runway to last?

Cash, cash equivalents and marketable securities were $287.7 million as of September 30, 2026. MacroGenics anticipates this amount, together with projected and anticipated future payments from partners, will support cash runway through 2028.

What payment did MacroGenics (MGNX) receive after Gilead exercised its option?

Gilead exercised an option under the companies’ 2022 collaboration agreement, triggering a $10.0 million payment to MacroGenics. The company remains eligible to earn additional milestones and royalties based on net product sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001125345FALSE00011253452026-11-122026-11-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
____________________

FORM 8-K
 
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  November 12, 2026
 
MACROGENICS, INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
001-36112
06-1591613
(State or Other Jurisdiction
of Incorporation)
(Commission
 File Number)
(IRS Employer
 Identification No.)

9704 Medical Center Drive
Rockville,Maryland20850
(Address of Principal Executive Offices)(Zip Code)

Registrant's telephone number, including area code:  (301) 251-5172
 
Not applicable 
(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
MGNX
Nasdaq Global Select Market
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02
Results of Operations and Financial Condition

On November 12, 2026, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01
Financial Statements and Exhibits
(d) Exhibits.
Exhibit NumberDescription of Exhibit
99.1
Press Release dated November 12, 2026
104Cover Page Interactive Data (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: November 12, 2026
MACROGENICS, INC.
By:
/s/ Jeffrey Peters
Jeffrey Peters
Senior Vice President, General Counsel and Corporate Secretary



Exhibit 99.1


macrogenics_logoxrgbxfullc.jpg


MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress

•Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two dose levels
•Reported interim results at ESMO in both Phase 1 study of MGC026 in heavily pretreated SCCHN patients and Phase 2 study of lorigerlimab in CCGC patients
•First patient dosed with MGC030 in Phase 1 study
•Strengthened Board with addition of two new independent directors with expertise in oncology drug discovery and development
•Cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026; cash runway guidance remains through 2028

ROCKVILLE, MD., November 12, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended September 30, 2026, and highlighted recent corporate progress.
“MacroGenics has made significant progress over the past year. We have strengthened our business, sharpened our pipeline development priorities, delivered on key strategic objectives and generated approximately $290 million in non-dilutive capital over the past 12 months,” said Eric Risser, President and Chief Executive Officer of MacroGenics. “We are grateful to our employees and partners for their dedication and contributions to this progress. Looking ahead, we believe MacroGenics is well positioned for a year of important milestones in 2027, with multiple opportunities to demonstrate the potential of our innovative pipeline while maintaining a disciplined approach to capital allocation.”

Advancement of Innovative Pipeline
MacroGenics is developing a portfolio of investigational agents, including novel topoisomerase I inhibitor-based antibody-drug conjugate (ADC), T-cell engager (TCE) and dual checkpoint inhibitor molecules.

•MGC028 is a first-in-class ADC targeting ADAM9, a protein that is overexpressed in multiple solid tumors. Phase 1 dose escalation of this molecule has been completed, and the Company has selected a lead indication. MacroGenics plans to initiate a randomized evaluation of two dose levels in this indication by year end 2026. As of a data cutoff of October 10, 2026, there were no dose-limiting toxicities, and no cases of ILD or ocular toxicity were reported. The Company intends to provide an interim clinical update, including efficacy and safety results in the lead indication, in the first half of 2027.







•MGC026 is a novel ADC targeting B7-H3, a protein expressed across the tumor microenvironment, including tumor-associated stroma and vasculature. Interim Phase 1 results were reported at the European Society for Medical Oncology (ESMO) 2026 Congress (link), including encouraging efficacy data and a manageable safety and tolerability profile in heavily pretreated squamous cell carcinoma of the head and neck (SCCHN) patients. The Company expects to complete enrollment of the ongoing 40-patient SCCHN Simon 2-stage monotherapy cohort by year end 2026, with updated data expected in mid-2027. In parallel, the Company will continue to evaluate the evolving competitive landscape and review the development and collaboration strategies for this molecule.

•MGC030 is a first-in-class ADC targeting an undisclosed antigen expressed across several solid tumors. Following clearance of the Investigational New Drug (IND) application, the first patient was dosed in a Phase 1 study in patients with advanced solid tumors, including urothelial, colorectal, gastric or gastroesophageal junction, esophageal and pancreatic cancers.

•Lorigerlimab is a PD-1 × CTLA-4 bispecific DART® molecule being evaluated in patients with advanced gynecologic cancers. At ESMO 2026, the Company reported interim Phase 2 results (link) demonstrating encouraging preliminary clinical activity with single-agent lorigerlimab dosed at 6 mg/kg every three weeks (Q3W) in clear cell gynecologic cancer (CCGC). The Company expects to complete enrollment of 20 CCGC patients at a lower dose of 3 mg/kg Q3W by year end 2026, and report updated results in the first half of 2027.

Future Pipeline

MacroGenics is advancing multiple preclinical programs that incorporate proprietary platforms for next-generation TCEs and ADCs. MGD032, a novel next-generation TCE against an undisclosed target, is advancing in IND-enabling studies.

Corporate and Collaboration Updates
•Appointment of New Independent Directors. In late October, MacroGenics appointed Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., two accomplished biopharmaceutical executives with extensive oncology drug development experience, to the Company’s Board of Directors. Drs. Kuriakose and Vasconcelles have established track records guiding innovative biotechnology companies through critical stages of growth and delivering substantial shareholder value.

•Gilead Collaboration. On August 11, the Company announced that Gilead Sciences, Inc. had exercised its option to license a preclinical bispecific program under the companies’ 2022 collaboration agreement. This option exercise triggered a $10.0 million payment to MacroGenics. The Company remains eligible to earn additional milestones and royalties based on net product sales.




Third Quarter 2026 Financial Results
•Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2026, were $287.7 million, compared to $189.9 million as of December 31, 2025. During the third quarter, the Company received $119.6 million in cash consideration from Bora in connection with the sale of its GMP manufacturing operations, $24.5 million as regulatory milestone payment from Sanofi and $10.0 million option license payment from Gilead.

•Revenue: Total revenue was $18.7 million for the quarter ended September 30, 2026, compared to $53.0 million for the quarter ended September 30, 2025. The decrease was primarily due to $50.0 million in milestone revenue recognized in 2025 under the Provention (Sanofi) Asset Purchase Agreement, compared to $10.0 million recognized in 2026 related to the option exercise under the Gilead Agreement, partially offset by a $5.3 million increase in ZYNYZ royalty revenue.

•R&D Expenses: Research and development expenses were $30.6 million for the quarter ended September 30, 2026, compared to $32.7 million for the quarter ended September 30, 2025. The decrease was primarily due to lower costs related to lorigerlimab, vobramitamab duocarmazine, MGC030 manufacturing and IND-enabling activities, and certain preclinical ADCs, partially offset by increased costs related to MGC026, MGC028, MGC030 clinical activities and certain next-generation T-cell engagers.

•G&A Expenses: General and administrative expenses were $8.4 million for the quarter ended September 30, 2026, compared to $9.9 million for the quarter ended September 30, 2025. The decrease was primarily due to lower personnel-related costs, including stock-based compensation expense.
•Net Income (Loss): Net loss was $20.1 million for the quarter ended September 30, 2026, compared to net income of $16.8 million for the quarter ended September 30, 2025.
•Shares Outstanding: Shares of common stock outstanding as of September 30, 2026, were 63,875,835.
•Cash Runway Guidance: MacroGenics anticipates that its cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026, in addition to projected and anticipated future payments from partners, will support its cash runway through 2028.



MACROGENICS, INC.
SELECTED CONSOLIDATED BALANCE SHEET DATA
(Amounts in thousands)



September 30, 2026December 31, 2025
(unaudited)
Cash, cash equivalents and marketable securities$287,680 $189,913 
Total assets318,685 256,846 
Deferred revenue55,503 56,779 
Total stockholders' equity25,151 55,591 




MACROGENICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)
(Amounts in thousands, except share and per share data)
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenues:
Collaborative and other agreements$10,085 $49,670 $36,142 $61,828 
Royalty revenue8,582 3,333 22,078 5,087 
Total revenues18,667 53,003 58,220 66,915 
Costs and expenses:
Research and development30,610 32,709 104,363 113,198 
General and administrative8,360 9,905 25,975 29,925 
Total costs and expenses38,970 42,614 130,338 143,123 
Income (loss) from operations(20,303)10,389 (72,118)(76,208)
Loss on extinguishment of royalty monetization liability— — (52,762)— 
Interest and other income2,912 1,528 5,834 4,620 
Interest and other expense(4,084)(3,342)(13,369)(4,236)
Income (loss) before income taxes(21,475)8,575 (132,415)(75,824)
Income tax provision— — — 105 
Net income (loss) from continuing operations(21,475)8,575 (132,415)(75,929)
Net income from discontinued operations, net of taxes1,399 8,247 95,080 15,464 
Net income (loss)(20,076)16,822 (37,335)(60,465)
Other comprehensive income (loss):
Unrealized gain (loss) on investments(293)12 (340)1 
Comprehensive income (loss)$(20,369)$16,834 $(37,675)$(60,464)
Net income (loss) per common share - basic
Net income (loss) from continuing operations$(0.34)$0.14 $(2.08)$(1.21)
Net income from discontinued operations0.02 0.13 1.50 0.25 
Net income (loss) per share - basic$(0.32)$0.27 $(0.58)$(0.96)
Net income (loss) per common share - diluted
Net income (loss) from continuing operations$(0.34)$0.14 $(2.08)$(1.21)
Net income from discontinued operations0.02 0.13 1.50 0.25 
Net income (loss) per share - diluted$(0.32)$0.27 $(0.58)$(0.96)
Weighted average common shares outstanding
Basic63,743,440 63,233,266 63,596,967 63,112,560 
Diluted 63,743,440 63,283,624 63,596,967 63,112,560 






About MacroGenics, Inc.

MacroGenics (the Company) is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com.MacroGenics, the MacroGenics logo and DART® are trademarks or registered trademarks of MacroGenics, Inc.

Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of and regulatory plans for the Company’s therapeutic candidates, expected timing of the release of clinical updates and safety and efficacy data for the Company’s ongoing clinical trials, anticipated cash runway and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential”, “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy, including our ability to execute on our key strategic priorities for 2026, constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks related to the reproducibility of any results initially seen in any product candidate; risks that any product candidate’s revenue, expenses and costs may not be as expected; risks relating to any product candidate’s market acceptance, competition, reimbursement and regulatory actions; future data or clinical updates for any product candidates, including timing and results of efficacy and safety data with respect to any product candidates in ongoing clinical trials; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations regarding the expansion of ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises; costs of litigation and the failure to successfully defend lawsuits and other claims against us; risks related to the transition of the CDMO operations to the purchaser following the sale of our CDMO operations; and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements



should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

CONTACTS

Jim Karrels, Senior Vice President, CFO
1-301-251-5172
info@macrogenics.com

Argot Partners
1-212-600-1902
macrogenics@argotpartners.com

Filing Exhibits & Attachments

4 documents

Keep reading